JPRN-UMIN000030522
Recruiting
未知
A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies - Sirolimus for intractable vascular anomalies
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Intractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lymphatic anomaly, Kaposiform lymphangiomatosis), Gorham-Stout disease, Kaposiform hemangioendothelioma and Tuffted angioma with Kasabach-Merritt phenomenon, Nenous malformation, Arteriovenous malformation, Klippel-Trenaunay-Weber syndrome,Bluerubber bleb nevus syndrome, Complex-combined vascular malformations
- Sponsor
- Gifu University
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Patients who currently have an uncontrolled infection 2\) Uncontrolled diabetes, uncontrolled hypertension, uncontrolled hyperlipidemia, chronic liver disease, or chronic renal disease 3\) History of allergy to sirolimus, or additive substance 4\) Known history of HIV seropositivity or known immunodeficiency 5\) Patients who have undergone surgical resection or interventional radiology procedures for target lesions within 2 weeks 6\) Pregnant, probably pregnant, or breast\-feeding woman. Patients who do not agree birth control during clinical trial. 7\) Patient who is judged inappropriate to participate in this study by the investigators
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 3
A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomaliesIntractable vascular anomaliesVascular disordersJPRN-jRCTs031180290Ozeki Michio130
Active, not recruiting
Phase 1
A multi-centre, open-label, single-arm study assessing the safety and efficacy of 5 mg of mifepristone for the treatment of endometriosis in reproductive-age women during two treatment cycles of 24 weeks eachendometriosis in reproductive-ageMedDRA version: 20.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersTherapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]EUCTR2020-004302-63-HUitaphar Laboratorios S.L.300
Active, not recruiting
Phase 3
Efficacy and safety of Sirolimus granules twice daily administration in patients with intractuable vascular malformationsIntractable vascular malformationsVascular disordersD054079JPRN-jRCTs031200055Mochizuki Shinji11
Not yet recruiting
Phase 4
A study of Romiplostim Powder for Injection in patientsCTRI/2021/08/035609Intas Pharmaceuticals Limited
Not yet recruiting
Phase 4
The aim is to evaluate the safety and efficacy of MeRes100™ Sirolimus Eluting BioResorbable Vascular Scaffold in coronary artery disease patients.It enhances coronary luminal diameter in symptomatic ischemic heart disease, addressing de novo lesions in native coronary arteries.Health Condition 1: I251- Atherosclerotic heart disease of native coronary arteryCTRI/2024/02/062438Meril Diagnostics Private Limited